<DOC>
	<DOCNO>NCT00193544</DOCNO>
	<brief_summary>In trial , plan evaluate role arsenic trioxide treatment patient refractory multiple myeloma . Arsenic trioxide use combination thalidomide . Although drug similar mechanism action , likely mechanism may additive synergistic . Since neither drug produce much myelosuppression , combination regimen tolerable patient compromise marrow function due involvement myeloma and/or previous cytotoxic chemotherapy</brief_summary>
	<brief_title>Arsenic Trioxide Thalidomide Treatment Refractory Multiple Myeloma</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : - Arsenic Trioxide + Thalidomide</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>To include study , must meet following criterion : Confirmed diagnosis multiple Myeloma Received least one previous chemotherapy regimen 3 previous Thalidomide without dexamethasone without chemotherapy factor total number regimen . Age least 18 year year Able perform activity daily live minimal assistance Life expectancy 3 month Adequate bone marrow , liver kidney function Must give write informed consent order participate . You participate study follow apply : Women pregnant lactating . Preexisting moderate neuropathy Patients significant underlying cardiac dysfunction Uncontrolled hypercalcemia Active serious infection control antibiotic History grand mal seizure ( infantile febrile seizure ) Receiving medication prolong QT interval . Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>